128 related articles for article (PubMed ID: 25004210)
1. Odds still favor Novartis heart failure drug Serelaxin.
Ratner M
Nat Biotechnol; 2014 Jul; 32(7):602-3. PubMed ID: 25004210
[No Abstract] [Full Text] [Related]
2. Serelaxin : a potential new drug for the treatment of acute heart failure.
Neverova N; Teerlink JR
Expert Opin Investig Drugs; 2014 Jul; 23(7):1017-26. PubMed ID: 24865798
[TBL] [Abstract][Full Text] [Related]
3. Serelaxin in acute heart failure: Most recent update on clinical and preclinical evidence.
Ghosh RK; Banerjee K; Tummala R; Ball S; Ravakhah K; Gupta A
Cardiovasc Ther; 2017 Feb; 35(1):55-63. PubMed ID: 27727514
[TBL] [Abstract][Full Text] [Related]
4. Serelaxin a novel treatment for acute heart failure.
Castrini AI; Carubelli V; Lazzarini V; Bonadei I; Lombardi C; Metra M
Expert Rev Clin Pharmacol; 2015; 8(5):549-57. PubMed ID: 26294074
[TBL] [Abstract][Full Text] [Related]
5. Relaxin for the Treatment of Acute Decompensated Heart Failure: Pharmacology, Mechanisms of Action, and Clinical Evidence.
Ng TM; Goland S; Elkayam U
Cardiol Rev; 2016; 24(4):194-204. PubMed ID: 26331289
[TBL] [Abstract][Full Text] [Related]
6. First clinical experience with intravenous recombinant human relaxin in compensated heart failure.
Dschietzig T; Teichman S; Unemori E; Wood S; Boehmer J; Richter C; Baumann G; Stangl K
Ann N Y Acad Sci; 2009 Apr; 1160():387-92. PubMed ID: 19416226
[TBL] [Abstract][Full Text] [Related]
7. Top heart-failure contender serelaxin flops.
Nat Biotechnol; 2017 Apr; 35(4):297. PubMed ID: 28398333
[No Abstract] [Full Text] [Related]
8. Serelaxin: new investigational treatment in acute heart failure.
Said S; Mukherjee D
Cardiovasc Hematol Agents Med Chem; 2013 Sep; 11(3):243-8. PubMed ID: 24289727
[TBL] [Abstract][Full Text] [Related]
9. Targeted biological therapies reach the heart: the case of serelaxin for heart failure.
Kumar VA; Wilson SS; Ayaz SI; Levy PD
Drugs Today (Barc); 2015 Oct; 51(10):591-7. PubMed ID: 26583301
[TBL] [Abstract][Full Text] [Related]
10. Emerging role of serelaxin in the therapeutic armamentarium for heart failure.
Varr BC; Maurer MS
Curr Atheroscler Rep; 2014 Oct; 16(10):447. PubMed ID: 25108571
[TBL] [Abstract][Full Text] [Related]
11. Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial.
Filippatos G; Farmakis D; Metra M; Cotter G; Davison BA; Felker GM; Greenberg BH; Hua TA; Pang PS; Ponikowski P; Qian M; Severin TA; Voors AA; Teerlink JR
Clin Res Cardiol; 2017 Jun; 106(6):444-456. PubMed ID: 28150186
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic effects of serelaxin in acute heart failure.
Du XJ; Hewitson TD; Nguyen MN; Samuel CS
Circ J; 2014; 78(3):542-52. PubMed ID: 24451687
[TBL] [Abstract][Full Text] [Related]
13. Serelaxin in clinical development: past, present and future.
Unemori E
Br J Pharmacol; 2017 May; 174(10):921-932. PubMed ID: 28009437
[TBL] [Abstract][Full Text] [Related]
14. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes.
Metra M; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Ponikowski P; Unemori E; Voors AA; Adams KF; Dorobantu MI; Grinfeld L; Jondeau G; Marmor A; Masip J; Pang PS; Werdan K; Prescott MF; Edwards C; Teichman SL; Trapani A; Bush CA; Saini R; Schumacher C; Severin T; Teerlink JR;
J Am Coll Cardiol; 2013 Jan; 61(2):196-206. PubMed ID: 23273292
[TBL] [Abstract][Full Text] [Related]
15. Serelaxin for the treatment of acute heart failure: a review with a focus on end-organ protection.
Díez J; Ruilope LM
Eur Heart J Cardiovasc Pharmacother; 2016 Apr; 2(2):119-30. PubMed ID: 27418970
[TBL] [Abstract][Full Text] [Related]
16. Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis.
Teerlink JR; Davison BA; Cotter G; Maggioni AP; Sato N; Chioncel O; Ertl G; Felker GM; Filippatos G; Greenberg BH; Pang PS; Ponikowski P; Edwards C; Senger S; Teichman SL; Nielsen OW; Voors AA; Metra M
Eur J Heart Fail; 2020 Feb; 22(2):315-329. PubMed ID: 31886953
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human H2 relaxin (serelaxin) as a cardiovascular drug: aiming at the right target.
Bani D
Drug Discov Today; 2020 Jul; 25(7):1239-1244. PubMed ID: 32360533
[TBL] [Abstract][Full Text] [Related]
18. Coreg. New indication for heart failure drug.
Nursing; 2002 Feb; 32(2):18. PubMed ID: 11924159
[No Abstract] [Full Text] [Related]
19. [The RELAX-AHF study].
Mortara A
G Ital Cardiol (Rome); 2015 Apr; 16(4):193-7. PubMed ID: 25959752
[No Abstract] [Full Text] [Related]
20. The rise and fall of Natrecor for congestive heart failure: implications for drug policy.
Kesselheim AS; Fischer MA; Avorn J
Health Aff (Millwood); 2006; 25(4):1095-102. PubMed ID: 16835191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
